Literature DB >> 28951499

A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention.

Christopher John Dunnill1,2, Wafaa Al-Tameemi1, Andrew Collett1,2, Iain Stuart Haslam1,2, Nikolaos Theodoros Georgopoulos3,2.   

Abstract

Chemotherapy-induced alopecia (CIA) is the most visibly distressing side effect of commonly administered chemotherapeutic agents. Because psychological health has huge relevance to lifestyle, diet, and self-esteem, it is important for clinicians to fully appreciate the psychological burden that CIA can place on patients. Here, for the first time to our knowledge, we provide a comprehensive review encompassing the molecular characteristics of the human hair follicle (HF), how different anticancer agents damage the HF to cause CIA, and subsequent HF pathophysiology, and we assess known and emerging prevention modalities that have aimed to reduce or prevent CIA. We argue that, at present, scalp cooling is the only safe and U.S. Food and Drug Administration-cleared modality available, and we highlight the extensive available clinical and experimental (biological) evidence for its efficacy. The likelihood of a patient that uses scalp cooling during chemotherapy maintaining enough hair to not require a wig is approximately 50%. This is despite different types of chemotherapy regimens, patient-specific differences, and possible lack of staff experience in effectively delivering scalp cooling. The increased use of scalp cooling and an understanding of how to deliver it most effectively to patients has enormous potential to ease the psychological burden of CIA, until other, more efficacious, equally safe treatments become available. IMPLICATIONS FOR PRACTICE: Chemotherapy-induced alopecia (CIA) represents perhaps the most distressing side effect of chemotherapeutic agents and is of huge concern to the majority of patients. Scalp cooling is currently the only safe option to combat CIA. Clinical and biological evidence suggests improvements can be made, including efficacy in delivering adequately low temperature to the scalp and patient-specific cap design. The increased use of scalp cooling, an understanding of how to deliver it most effectively, and biological evidence-based approaches to improve its efficacy have enormous potential to ease the psychological burden of CIA, as this could lead to improvements in treatment and patient quality-of-life. © AlphaMed Press 2017.

Entities:  

Keywords:  Cell models; Chemotherapy; Chemotherapy‐induced alopecia; Hair follicle; Hair loss; Prevention; Safety; Scalp cooling; Side effects; Toxicity

Mesh:

Substances:

Year:  2017        PMID: 28951499      PMCID: PMC5759815          DOI: 10.1634/theoncologist.2017-0263

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  120 in total

Review 1.  In search of the "hair cycle clock": a guided tour.

Authors:  Ralf Paus; Kerstin Foitzik
Journal:  Differentiation       Date:  2004-12       Impact factor: 3.880

Review 2.  Regenerative medicine and hair loss: how hair follicle culture has advanced our understanding of treatment options for androgenetic alopecia.

Authors:  Claire A Higgins; Angela M Christiano
Journal:  Regen Med       Date:  2014-01       Impact factor: 3.806

3.  Permanent alopecia after busulfan chemotherapy.

Authors:  A Tosti; B M Piraccini; C Vincenzi; C Misciali
Journal:  Br J Dermatol       Date:  2005-05       Impact factor: 9.302

4.  Permanent alopecia following chemotherapy and bone marrow transplantation.

Authors:  D Tran; R D Sinclair; A P Schwarer; C W Chow
Journal:  Australas J Dermatol       Date:  2000-05       Impact factor: 2.875

Review 5.  Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis.

Authors:  Hyoseung Shin; Seong Jin Jo; Do Hun Kim; Ohsang Kwon; Seung-Kwon Myung
Journal:  Int J Cancer       Date:  2014-08-11       Impact factor: 7.396

Review 6.  Depression and cancer: mechanisms and disease progression.

Authors:  David Spiegel; Janine Giese-Davis
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

Review 7.  The symptom experience of alopecia.

Authors:  S Pickard-Holley
Journal:  Semin Oncol Nurs       Date:  1995-11       Impact factor: 2.315

Review 8.  Pathobiology of chemotherapy-induced hair loss.

Authors:  Ralf Paus; Iain S Haslam; Andrey A Sharov; Vladimir A Botchkarev
Journal:  Lancet Oncol       Date:  2013-02       Impact factor: 41.316

9.  Probing the effects of stress mediators on the human hair follicle: substance P holds central position.

Authors:  Eva M J Peters; Sofia Liotiri; Eniko Bodó; Evelin Hagen; Tamás Bíró; Petra C Arck; Ralf Paus
Journal:  Am J Pathol       Date:  2007-11-30       Impact factor: 4.307

10.  Maintenance of skin xenografts of widely divergent phylogenetic origin of congenitally athymic (nude) mice.

Authors:  D D Manning; N D Reed; C F Shaffer
Journal:  J Exp Med       Date:  1973-08-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review.

Authors:  C Paterson; M Kozlovskaia; M Turner; K Strickland; C Roberts; R Ogilvie; G Pranavan; P Craft
Journal:  J Cancer Surviv       Date:  2020-07-18       Impact factor: 4.442

2.  Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT).

Authors:  Danbee Kang; Im-Ryung Kim; Yeon Hee Park; Young Hyuck Im; Di Zhao; Eliseo Guallar; Jin Seok Ahn; Juhee Cho
Journal:  Support Care Cancer       Date:  2019-07-23       Impact factor: 3.603

3.  Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection.

Authors:  Arzu Cakir; Melisa Tuncer; Hilal Taymaz-Nikerel; Ozlem Ulucan
Journal:  Pharmacogenomics J       Date:  2021-06-21       Impact factor: 3.550

4.  Why Do Not All Chemotherapy Patients Lose Their Hair? Answering an Intriguing Question.

Authors:  Alfredo Rebora; Marcella Guarrera
Journal:  Skin Appendage Disord       Date:  2021-05-06

5.  Improving Information Provision on Chemotherapy-Induced Alopecia and Scalp Cooling: A Comprehensive Approach Including A Website and Web-Based Decision Tool.

Authors:  Corina van den Hurk; Paulien Keizer-Heldens; Ilse Raats; Kim Hoeijmakers; Floortje Mols
Journal:  Asia Pac J Oncol Nurs       Date:  2019 Oct-Dec

Review 6.  Scalp cooling to prevent chemotherapy-induced alopecia.

Authors:  Giselle de Barros Silva; Kathryn Ciccolini; Aline Donati; Corina van den Hurk
Journal:  An Bras Dermatol       Date:  2020-06-16       Impact factor: 1.896

7.  One-pot synthesis of biodegradable polydopamine-doped mesoporous silica nanocomposites (PMSNs) as pH-sensitive targeting drug nanocarriers for synergistic chemo-photothermal therapy.

Authors:  Huicong Zhang; Xuandong Wang; Peiyuan Wang; Rong Liu; Xuemei Hou; Wei Cao; Rong Zhong; Xiaolong Liu; Yun Zhang
Journal:  RSC Adv       Date:  2018-11-07       Impact factor: 4.036

8.  Mucoadhesive-to-penetrating controllable peptosomes-in-microspheres co-loaded with anti-miR-31 oligonucleotide and Curcumin for targeted colorectal cancer therapy.

Authors:  Ran Zhao; Sujuan Du; Ying Liu; Cong Lv; Yongli Song; Xinchun Chen; Bing Zhang; Dan Li; Shan Gao; Wei Cui; Maksim V Plikus; Xiaohua Hou; Kaichun Wu; Zhanju Liu; Zhihua Liu; Yingzi Cong; Yuan Li; Zhengquan Yu
Journal:  Theranostics       Date:  2020-02-18       Impact factor: 11.556

9.  Cooling-mediated protection from chemotherapy drug-induced cytotoxicity in human keratinocytes by inhibition of cellular drug uptake.

Authors:  Christopher Dunnill; Khalidah Ibraheem; Michael Peake; Myria Ioannou; Megan Palmer; Adrian Smith; Andrew Collett; Nikolaos T Georgopoulos
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.